Participants are excluded from the study if any of the following criteria apply:
- Participant has conditions that would adversely affect study participation such as
short life expectancy.
- Evidence of infection with human immunodeficiency virus (HIV), transplantation,
progressive multifocal leukoencephalopathy (PML), active hepatitis B or C, active or latent tuberculosis or other active infection that would adversely affect study participation.
- Persistent chronic or active or recurring system infection that may adversely affect
participation or IMP administration in this study as judged by the investigator
- History of malignancy within 5 years prior to screening. - History of alcohol or drug abuse within 1 year prior to Screening. - Hospitalized for psychiatric disease within 2 years prior to Screening. - Clinically significant laboratory abnormalities (including evidence of liver injury)
or electrocardiogram abnormalities at Screening.
- A bleeding disorder or known platelet dysfunction at any time prior to the screening
visit.
- A platelet count <150 000/μL at the screening visit. - A history of significant bleeding event within 6 months prior to screening, according
to the Investigator's judgment such as, but not limited to cerebral or gastrointestinal
- Lymphocyte count below the lower limit of normal at Screening. - Recent live (attenuated) vaccine within 2 months before the first treatment visit. - Recent major surgery (within 4 weeks of Screening) or planned major surgery during the
study.
- The participant has received medications/treatments for MS within a specified time
frame.
- Receiving potent and moderate inducers of cytochrome P450 3A (CYP3A) or potent
inhibitors of CYP2C8 hepatic enzymes.
- Receiving anticoagulant or antiplatelet therapy (such as aspirin >81mg/day,
clopidogrel, warfarin).
- Contraindications to magnetic resonance imaging (MRI). NOTE: Other Inclusion/Exclusion
criteria may apply. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial